Cargando…

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe

Aims: Cardiovascular outcome trials with anti-diabetic drugs suggest that additional cardiovascular benefit can be achieved independent of improving glycaemic control. Nonetheless, dose selection of anti-diabetic drugs is typically based solely on glycaemic effects. We evaluated whether off-target d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koomen, Jeroen V., Stevens, Jasper, Monster-Simons, Margje H., Heerspink, Hiddo J. L., Mol, Peter G. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113630/ https://www.ncbi.nlm.nih.gov/pubmed/33995023 http://dx.doi.org/10.3389/fphar.2021.626766

Ejemplares similares

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment
por: Weersink, Rianne A., et al.
Publicado: (2019)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Justification of CT practices across Europe: results of a survey of national competent authorities and radiology societies
por: Foley, Shane J., et al.
Publicado: (2022)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
por: Mol, Peter G. M., et al.
Publicado: (2018)

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2019)

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020
por: Bakker, Elisabeth, et al.
Publicado: (2023)

Corrigendum: Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2020)

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
por: Koomen, Jeroen V., et al.
Publicado: (2019)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017)

Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe
por: Jonker, Carla J., et al.
Publicado: (2022)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting
por: Bakker, Elisabeth, et al.
Publicado: (2021)

The justification of induction
Publicado: (1974)

Knowledge and justification /
Publicado: (1994)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2019)

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia
por: Xiao, Alan J., et al.
Publicado: (2016)

Justification of empiric methodology to determine dexmedetomidine dose for the TREX study
por: Disma, Nicola, et al.
Publicado: (2022)

Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
por: Lee, Mijin, et al.
Publicado: (2023)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

South African Regulatory Authority: The Impact of Reliance on the Review Process Leading to Improved Patient Access
por: Keyter, Andrea, et al.
Publicado: (2021)

Assessing System Justification in Czech Population Using the System Justification Scale
por: Remr, Jiri
Publicado: (2023)

The justification of scientific change
por: Kordig, Carl R.
Publicado: (1971)

Basic Salaries - Justification
Publicado: (1955)

Physics'Justification for LEP
Publicado: (1979)

Physics'Justification for LEP
Publicado: (1979)

Is there justification for universal leukoreduction?
por: Mendrone, Alfredo, et al.
Publicado: (2014)

The logic of epistemic justification
por: Smith, Martin
Publicado: (2017)

Graded epistemic justification
por: Hawthorne, John, et al.
Publicado: (2020)

The System Justification Conundrum: Re-Examining the Cognitive Dissonance Basis for System Justification
por: Owuamalam, Chuma K., et al.
Publicado: (2016)

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion
por: Weersink, Rianne A, et al.
Publicado: (2016)

Phase III Trial of Albumin in Malaria Still Lacks Scientific Justification
por: Woodrow, Charles J, et al.
Publicado: (2007)

What are the justifications for distributed processing?
por: Langsford, A
Publicado: (1976)

Justification logic: reasoning with reasons
por: Artemov, Sergei, et al.
Publicado: (2019)

Justification for the PS exploitation budget.
por: Allardyce, B W
Publicado: (1994)

Honesty saves time (and justifications)
por: Foerster, Anna, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cinhaa9pa4445onckev8va5e1t